Pages that link to "Q42548473"

The following pages link to Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo (Q42548473):

Displaying 35 items.

• Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries (Q27001286) (← links)
• A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine (Q28343476) (← links)
• Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase (Q28369167) (← links)
• A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine (Q28379499) (← links)
• Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda (Q28535266) (← links)
• HIV-1 drug resistance and resistance testing (Q30245693) (← links)
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management. (Q33588535) (← links)
• Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity (Q33794922) (← links)
• Structure-based inhibitor design (Q33834114) (← links)
• N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations (Q33869951) (← links)
• HIV drug resistance and viral fitness. (Q34050677) (← links)
• Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine (Q34251987) (← links)
• Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. (Q34289052) (← links)
• Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase (Q34339657) (← links)
• Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. (Q34465037) (← links)
• HIV-1 genotypic and phenotypic resistance (Q34876000) (← links)
• Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase (Q35566910) (← links)
• Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance (Q35699612) (← links)
• Retrovirus reverse transcriptases containing a modified YXDD motif (Q36186797) (← links)
• Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses (Q36485086) (← links)
• Disease management--constructing optimal NRTI-based combinations: past, present, and future. (Q36568414) (← links)
• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future (Q37381677) (← links)
• A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. (Q39471491) (← links)
• Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. (Q39550164) (← links)
• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy (Q39557921) (← links)
• Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection (Q39591902) (← links)
• Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase (Q40013658) (← links)
• Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase (Q41495257) (← links)
• A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation. (Q41862836) (← links)
• Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease (Q42120771) (← links)
• The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response (Q43993272) (← links)
• Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance (Q44443514) (← links)
• Anti-human immunodeficiency virus drug combination strategies (Q45752028) (← links)
• Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands. (Q47936109) (← links)
• Antiretroviral Drug Resistance in HIV-1 (Q73235205) (← links)